Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 460.00
Bid: 440.00
Ask: 480.00
Change: -15.00 (-3.19%)
Spread: 40.00 (9.09%)
Open: 460.00
High: 470.00
Low: 455.00
Yest. Close: 470.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Faron Pharmaceuticals To Raise EUR2.1 Million For Clevegen Development

(Alliance News) - Faron Pharmaceuticals Oy on Monday announced a EUR1.1 million subscription and EUR2.0 million open offer to fund the clinical development of cancer drug Clevegen.Shares in

5 Aug 19 12:26

WINNERS & LOSERS SUMMARY: Thomas Cook Plunges On Rescue Deal Talks

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------BHP up 1.5%. The -

12 Jul 19 10:35

Faron Pharma Pleased By MATINS Progress And Plans To Increase Capacity

(Alliance News) - Faron Pharmaceuticals Oy said on Friday its MATINS study of nine cancer patients is progressing well, and it is planning to expand the clinical trial to more countries.The

12 Jul 19 10:20

Faron Pharmaceuticals Says Traumakine Study Hindered By Steroid Use

(Alliance News) - Faron Pharmaceuticals Oy on Wednesday said interim results from its phase two Inforaaa study support continuation but the study is limited by a lack of patients not also taking a

26 Jun 19 11:52

Faron Pharmaceuticals' Analysis Explains "Disappointing" Prior Trial

(Alliance News) - Faron Pharmaceuticals Oy on Friday said analysis of a more recent trial of Traumakine has explained why the drug did not perform as expected in a previous trial.Shares in

14 Jun 19 11:54

Faron Pharmaceuticals reports 'significant' findings from YODA study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced results from its pharmacokinetic/dynamic 'YODA' study examining the administration of concomitant steroids and Traumakine in healthy volunteers on Friday.

14 Jun 19 10:37

Faron Pharma Finance Head Wichmann Steps Down, Hanninen Replaces

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Friday said it has made several managerial changes, which it believes will strengthen its operating performance.The clinical stage said

24 May 19 13:34

Faron appoints new CFO after some internal shuffling

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals updated the market on its board and management team on Friday, announcing that Yrjö Wichmann was leaving his current role as its chief financial officer to take up the new position of vice-president, financing and investor relations.

24 May 19 11:50

Faron Pharmaceuticals Raises EUR1.3 Million Via Share Subscription (ALLISS)

LONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Ltd said Tuesday that it has raised EUR1.3 million via share subscription.The company has issued 1.8 million shares

14 May 19 14:16

Faron Pharmaceuticals Narrows Loss On Reduced Clinical Trial Costs

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Tuesday reported a slightly narrowed annual loss as the drug developer's research & development costs fell.Faron is a clinical

7 May 19 11:44

Faron Pharmaceuticals Knows Of No Reason For 43% Share Price Jump

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.Faron noted Thursday's 43% share price rise, and said

2 May 19 17:30

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 1 May J SainsburyFull Year ResultsConnect GroupHalf Year GroupQ1 Stock

30 Apr 19 16:02

Faron Gets Results Of Traumakine Study From Japanese Licensing Partner

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical trial results on its phase three Traumakine for

29 Apr 19 15:46

Faron Pharmaceuticals To Focus On Colorectal Cancer In Clevegen Trial

LONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.The testing of Clevegen on patients with will

11 Apr 19 12:13

Faron Pharmaceuticals upbeat on latest info from MATINS trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Thursday that the cohort expansion part of its phase 1 and 2 'MATINS' clinical trial, investigating the safety and efficacy of its wholly-owned novel precision cancer immunotherapy 'Clevegen', would begin with patients suffering from late-stage colorectal cancer as soon as the optimal dosing was determined.

11 Apr 19 11:22

Login to your account

Don't have an account? Click here to register.